Eric Swayze - Jan 31, 2024 Form 4 Insider Report for IONIS PHARMACEUTICALS INC (IONS)

Signature
By: Patrick R. O'Neil, attorney-in-fact For: Eric Swayze
Stock symbol
IONS
Transactions as of
Jan 31, 2024
Transactions value $
-$654,709
Form type
4
Date filed
2/2/2024, 07:55 PM
Previous filing
Jan 18, 2024
Next filing
Sep 4, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IONS Common Stock Sale -$560K -10.8K -24.89% $52.00 32.5K Jan 31, 2024 Direct
transaction IONS Common Stock Award $0 +3.72K +11.43% $0.00 36.2K Feb 1, 2024 Direct F1
transaction IONS Common Stock Sale -$94.5K -1.91K -5.26% $49.56 34.3K Feb 2, 2024 Direct F2, F3
holding IONS Common Stock 85 Jan 31, 2024 by Son
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Represents shares earned upon the vesting of performance-based restricted stock units ("PRSUs") for the second performance period of the grant to the reporting person reported on January 19, 2022. The Compensation Committee certified achievement of the pre-established performance goal based on the Issuer's relative total shareholder return as compared to a peer group of companies at a level resulting in a vest of 150% of target shares. As reported at grant, the PRSUs could result in a payout of 0% to 150% based on actual achievement of the goal.
F2 The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Performance restricted Stock Unit Agreement and Grant Notice.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.55 to $49.57 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.